- Home
- APVO vs JAGX Comparison
APVO vs JAGX Comparison
Compare APVO & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- JAGX
- Stock Information
- Founded
- APVO 2016
- JAGX 2013
- Country
- APVO United States
- JAGX United States
- Employees
- APVO N/A
- JAGX N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- JAGX Health Care
- Exchange
- APVO Nasdaq
- JAGX Nasdaq
- Market Cap
- APVO 4.1M
- JAGX 3.5M
- IPO Year
- APVO N/A
- JAGX N/A
- Fundamental
- Price
- APVO $3.23
- JAGX $2.54
- Analyst Decision
- APVO Strong Buy
- JAGX Strong Buy
- Analyst Count
- APVO 1
- JAGX 1
- Target Price
- APVO $5,920.00
- JAGX $60.00
- AVG Volume (30 Days)
- APVO 6.7M
- JAGX 87.2K
- Earning Date
- APVO 08-07-2025
- JAGX 08-12-2025
- Dividend Yield
- APVO N/A
- JAGX N/A
- EPS Growth
- APVO N/A
- JAGX N/A
- EPS
- APVO N/A
- JAGX N/A
- Revenue
- APVO N/A
- JAGX $11,552,000.00
- Revenue This Year
- APVO N/A
- JAGX $22.41
- Revenue Next Year
- APVO N/A
- JAGX $30.00
- P/E Ratio
- APVO N/A
- JAGX N/A
- Revenue Growth
- APVO N/A
- JAGX 13.93
- 52 Week Low
- APVO $2.81
- JAGX $2.43
- 52 Week High
- APVO $485.37
- JAGX $110.75
- Technical
- Relative Strength Index (RSI)
- APVO 34.28
- JAGX 27.84
- Support Level
- APVO $2.81
- JAGX $2.43
- Resistance Level
- APVO $13.11
- JAGX $3.30
- Average True Range (ATR)
- APVO 1.10
- JAGX 0.26
- MACD
- APVO 0.30
- JAGX 0.06
- Stochastic Oscillator
- APVO 4.08
- JAGX 7.05
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.